SynthesisJournal of endocrinological investigation2020
Prevalence of other autoimmune diseases in polyglandular autoimmune syndromes type II and III.
Synthesis in Journal of endocrinological investigation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.
- The Association Between COVID-19 and Thyroxine Levels: A Meta-Analysis.Frontiers in endocrinology · 2021Pooled it
- Multiplex Autoantibody Detection in Patients with Autoimmune Polyglandular Syndromes.International journal of molecular sciences · 2021Trial
- A Rare Case of Possible Iron Overload and B12 Deficiency in Autoimmune Polyglandular Syndrome Type 3B.Cureus · 2026Article
- Article
- Clinical and serological characteristics of type 3 APS, isolated T1DM and LADY/LADA.BMC endocrine disorders · 2025Article
- Systematic Analysis and Network Mapping of Disease Associations in Autoimmune Polyglandular Syndrome.The Journal of clinical endocrinology and metabolism · 2025Article
- Diverse clinical manifestations and management strategies in autoimmune polyglandular syndrome: a review of cases.Annals of medicine and surgery (2012) · 2025Review
- Diabetic Ketoacidosis With Schmidt Syndrome: An Autoimmune Polyendocrine Syndrome Type 2.Cureus · 2025Article
- Autoimmune Polyglandular Syndrome Type 2 Presentation with Alopecia Universalis, Hashimoto's Disease, and Addison's Disease.International medical case reports journal · 2025Article
- Type 3 autoimmune polyglandular syndrome (APS-3) or type 3 multiple autoimmune syndrome (MAS-3): an expanding galaxy.Journal of endocrinological investigation · 2023Review
- Hashimoto's thyroiditis, vitiligo, anemia, pituitary hyperplasia, and lupus nephritis-A case report of autoimmune polyglandular syndrome type III C + D and literature review.Frontiers in pediatrics · 2023Article
- Autoimmune Disease Classification Based on PubMed Text Mining.Journal of clinical medicine · 2022Article
- Superior Mesenteric Artery Syndrome Accompanied by Acute-onset Type 1 Diabetes Complicated with Graves' Disease.Internal medicine (Tokyo, Japan) · 2022Article
- Guillain-Barré syndrome and myasthenia gravis in the context of autoimmune polyendocrine syndrome type III.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2021Article
- Thyroid disease in the time of COVID-19.Endocrine · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
purposePolyglandular autoimmune syndromes (PAS) are complex, heterogeneous disorders in which various autoimmune diseases can occur, affecting both endocrine and non-endocrine organs. In this meta-analysis, the prevalence of associated autoimmune disorders was investigated in PAS II and III.
methodsA comprehensive search in MEDLINE and Embase databases identified 479 studies with the keywords of PAS II and PAS III. 18 records containing a total of 1312 patients fulfilled our inclusion criteria (original studies reporting at least 10 cases and containing the combination of other autoimmune disorders) and were selected for further analysis. A meta-analysis of prevalence was performed using the random-effects model with the calculation of 95% confidence intervals (CI). Results of each meta-analysis were displayed graphically using forest plots.
resultsDistinction between PAS II and PAS III was made in 842 cases, of which 177 and 665 were PAS II and III (21.1 vs 78.9%), respectively. The prevalence of Hashimoto's thyroiditis was significantly higher than that of Graves's disease (39% [95% CI 17-65%] vs. 4% [95% CI 0-10%], respectively; p = 0.001). In PAS II, Addison's disease (AD) coexisted with AITDs, T1DM or the combination of these conditions in 65, 18 and 10% of cases, respectively. In addition, one other endocrine and five non-endocrine organ-specific autoimmune disorders were reported. In PAS III, two other autoimmune endocrinopathies, six non-endocrine organ-specific, and four systemic autoimmune disorders were found in combination with AITDs.
conclusionsAITDs, T1DM and AD are the most common combinations in PAS, thus screening for these conditions seems to be reasonable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.